Market Place
Sourcing Support
Clearmind Medicine Announces 1-For-10 Reverse Share Split
19 May 2026 //
GLOBENEWSWIRE
Clearmind Medicine to Study MEAI with Tirzepatide vs GLP-1 Drugs
18 May 2026 //
GLOBENEWSWIRE
Clearmind Reaches 20-Patient Trial Milestone
12 May 2026 //
GLOBENEWSWIRE
Clearmind Seeks FDA Breakthrough Tag for MEAI Therapy
27 Apr 2026 //
FIRSTWORD PHARMA
Clearmind Medicine Reports Positive Safety Board Recommendation
15 Apr 2026 //
GLOBENEWSWIRE
Clearmind Medicine`s CMND-100 Succeeds In FDA Phase I/Iia Trial
14 Apr 2026 //
GLOBENEWSWIRE
Clearmind Medicine Completes Phase I/Iia Trial Of CMND-100
30 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Seeks Patent In India For Psychedelic Compound
27 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Updates Progress In Fda-Approved CMND-100
19 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Publishes Six Innovative Patents In Hong Kong
17 Mar 2026 //
GLOBENEWSWIRE
Scisparc, Clearmind Medicine Partner For Depression Therapy
16 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Files Hong Kong Patent For Depression Therapy
13 Mar 2026 //
GLOBENEWSWIRE
NeuroThera Labs, Clearmind Announce Weight Loss Patent
12 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Advances to CMND-100 Trial`s Third Cohort
11 Mar 2026 //
GLOBENEWSWIRE
Clearmind Advances to Next Trial Phase on DSMB Nod
04 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Reports Positive Safety Data For CMND-100
09 Feb 2026 //
GLOBENEWSWIRE
Clearmind Medicine Partners To Develop Intranasal MEAI
06 Feb 2026 //
GLOBENEWSWIRE
Polyrizon Inks Deal For Intranasal Neuroplastogen Formulation
06 Feb 2026 //
GLOBENEWSWIRE
Clearmind MEAI Added to US Congress Bill on Emerging Therapies
03 Feb 2026 //
GLOBENEWSWIRE
Clearmind Medicine Inc. Submits Form 20-F For Fy 2025
20 Jan 2026 //
GLOBENEWSWIRE
Clearmind Medicine Completes Phase I/IIa Trial For CMND-100
14 Jan 2026 //
GLOBENEWSWIRE
Clearmind Medicine Restores Nasdaq Minimum Bid Price Compliance
31 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine Advances Clinically, Expands Globally
24 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine Finishes FDA Phase I/IIa Cohort 2 for MEAI
16 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine`s MEAI Spotlighted in Prestigious Review
12 Dec 2025 //
GLOBENEWSWIRE
Clearmind Pharma Restores Nasdaq Stockholders` Equity Compliance
12 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine Announces 1-For-40 Reverse Share Split
10 Dec 2025 //
GLOBENEWSWIRE
Clearmind Pharma Receives Nasdaq Minimum Bid Price Notice
05 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine Progresses CMND-100 To Dosing Phase
02 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine Charges Forward in Alcoholism Treatment
01 Dec 2025 //
GLOBENEWSWIRE
Clearmind Medicine Starts AUD Trial in Tel Aviv Clinic
25 Nov 2025 //
GLOBENEWSWIRE
Clearmind DSMB OKs Ph1/2a CMND-100 Trial After Positive Review
24 Nov 2025 //
GLOBENEWSWIRE
Neurothera, Clearmind Secure Patent for Novel Depression Therapy
20 Nov 2025 //
GLOBENEWSWIRE
Clearmind Adds Fifth Site to Accelerate FDA-Approved AUD Trial
20 Nov 2025 //
GLOBENEWSWIRE
Clearmind Posts Positive Top-Line Data in AUD Ph1/2a Trial
18 Nov 2025 //
GLOBENEWSWIRE
Clearmind Files Patent for Non-Hallucinogenic Psychedelic Drug
17 Nov 2025 //
GLOBENEWSWIRE
Clearmind Expands FDA-Regulated Ph1/2A Trial for Alcohol Use
13 Nov 2025 //
GLOBENEWSWIRE
Clearmind Medicine Completes First Cohort Treatment in AUD
10 Nov 2025 //
GLOBENEWSWIRE
Clearmind Medicine Notified Of Nasdaq Stockholders` Equity
06 Nov 2025 //
GLOBENEWSWIRE
Clearmind Enhances MEAI Depression Treatment IP Protection
05 Nov 2025 //
GLOBENEWSWIRE
Clearmind Files US Patent for Non-Hallucinogenic MEAI Therapy
31 Oct 2025 //
GLOBENEWSWIRE
Clearmind Medicine Wraps First Cohort Treatment In FDA-Approved
30 Oct 2025 //
GLOBENEWSWIRE
Clearmind Medicine CEO To Speak at Webinar
28 Oct 2025 //
GLOBENEWSWIRE
Clearmind Pharma Appoints Mary-Elizabeth Gifford as Chief
27 Oct 2025 //
GLOBENEWSWIRE
Clearmind Enrolls Last Patient in FDA Ph1/2a Trial for AUD
21 Oct 2025 //
GLOBENEWSWIRE
Scisparc & Clearmind Collaborate On US Patent For Binge Behavior
20 Oct 2025 //
GLOBENEWSWIRE
Clearmind Medicine Convenes First Scientific Advisory Board
25 Sep 2025 //
GLOBENEWSWIRE
Clearmind Medicine Secures $10M for Strategic Opportunities
19 Sep 2025 //
GLOBENEWSWIRE
SciSparc, Clearmind Patent Novel Combo for Obesity, Sugar
07 Aug 2025 //
GLOBENEWSWIRE
Clearmind Medicine Publishes Patent for Combo Therapy Targeting
07 Aug 2025 //
GLOBENEWSWIRE
Clearmind Gets IRB OK for Ph 1/2a Alcohol Use Disorder Trial
05 Aug 2025 //
GLOBENEWSWIRE
SciSparc-Clearmind Patent for Weight Loss, Fatty Liver Therapy
30 Jul 2025 //
GLOBENEWSWIRE
Clearmind Opens Israeli Site for CMND-100 Alcohol Trial
23 Jul 2025 //
GLOBENEWSWIRE
Clearmind Expands Alcohol Use Trial with New Site & Participant
15 Jul 2025 //
GLOBENEWSWIRE
Clearmind Gets IRB Approval for Alcohol Disorder Trial in Israel
03 Jul 2025 //
GLOBENEWSWIRE
Clearmind Medicine Doses First Patient in Alcohol Disorder Trial
30 Jun 2025 //
GLOBENEWSWIRE
Clearmind Medicine Expands Global Alcohol Use Disorder Trial
27 Jun 2025 //
GLOBENEWSWIRE
Clearmind Medicine Enrolls First Patient in Alcoholism Treatment
25 Jun 2025 //
GLOBENEWSWIRE
Clearmind Teams with Political Firm to Back Psychedelics
24 Jun 2025 //
GLOBENEWSWIRE
Clearmind Adds Israeli Site to Alcohol Use Disorder Trial
23 Jun 2025 //
GLOBENEWSWIRE
